Compare AbbVie Inc (ABBV) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs KKR & Co Inc — how do they compare? AbbVie Inc trades at $249.52 (market cap $441.94B), while KKR & Co Inc trades at $109.79 (market cap $99.61B). The key difference: AbbVie Inc is far larger — about 4.4× KKR & Co Inc's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | KKR | |
|---|---|---|
Market Cap | $441.94B | $99.61B |
Sector | Health | Financials |
52-Week High | $263.58 | $149.34 |
52-Week Low | $197.38 | $83.88 |
Enterprise Value | $506.19B | $22.17B |
Dividend Yield | 2.77% | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
KKR trades at $103.83, up 0.99% with strong bullish momentum. The stock shows robust earnings performance with Q2 2026 EPS of $1.63 beating estimates of $1.43, continuing a trend of positive surprises. Recent acquisitions including Integer Holdings ($4.3B) and Medicover India ($1.39B) demonstrate aggressive growth strategy. Analyst consensus remains overwhelmingly bullish with 24 buy ratings and $127.22 price target, representing 22.5% upside potential from current levels.
KKR presents compelling investment opportunity with strong fundamentals, consistent earnings beats, and strategic acquisitions driving growth. Key risks include integration challenges from recent deals, market volatility affecting asset management fees, and potential regulatory scrutiny of private equity operations. The company's $19.2B infrastructure fund closure signals strong institutional confidence in long-term strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
